Zhiyi Pharmaceutics

About:

Zhiyi Pharmaceutics focuses on the research and development of second-generation probiotics and Live Biotherapeutics.

Top Investors: Shenzhen Capital Group, SDIC Venture Capital, Guangdong Technology Financial Group, Sinoking Capital, Hejun Capital

Description:

Founded in 2013, Zhiyi Bio focuses on the research and development of second-generation probiotics and Live Biotherapeutics. Based on the discovery of strains and drug development with independent intellectual property rights, a lot of innovative research has been carried out, and the “Know-How” from strains to drugs has been established, and the innovative live bacteria drug SK08 is about to enter the clinic. On this basis, Zhiyi will continue to strengthen the research and development of the relationship between human microbiome and disease, including microbial culture group and pathobionts research, target determination and separation of new functional strains.

Total Funding Amount:

560M CNY

Headquarters Location:

Guangzhou, Guangdong, China

Founded Date:

2013-01-01

Contact Email:

public(AT)zypharm.com.cn

Founders:

Ye Wang

Number of Employees:

1-10

Last Funding Date:

2024-03-28

IPO Status:

Private

Industries: